Dendritic cells in the periphery control antigen-specific natural and induced regulatory T cells.

Front Immunol

Department of Geriatric and Environmental Dermatology, Graduate School of Medical Sciences, Nagoya City University, Nagoya , Japan.

Published: June 2013

Dendritic cells (DCs) are specialized antigen-presenting cells that regulate both immunity and tolerance. DCs in the periphery play a key role in expanding naturally occurring Foxp3(+) CD25(+) CD4(+) regulatory T cells (Natural T-regs) and inducing Foxp3 expression (Induced T-regs) in Foxp3(-) CD4(+) T cells. DCs are phenotypically and functionally heterogeneous, and further classified into several subsets depending on distinct marker expression and their location. Recent findings indicate the presence of specialized DC subsets that act to expand Natural T-regs or induce Foxp3(+) T-regs from Foxp3(-) CD4(+) T cells. For example, two major subsets of DCs in lymphoid organs act differentially in inducing Foxp3(+) T-regs from Foxp3(-) cells or expanding Natural T-regs with model-antigen delivery by anti-DC subset monoclonal antibodies in vivo. Furthermore, DCs expressing CD103 in the intestine induce Foxp3(+) T-regs from Foxp3(-) CD4(+) T cells with endogenous TGF-β and retinoic acid. In addition, antigen-presenting DCs have a capacity to generate Foxp3(+) T-regs in the oral cavity where many antigens and commensals exist, similar to intestine and skin. In skin and skin-draining lymph nodes, at least six DC subsets have been identified, suggesting a complex DC-T-reg network. Here, we will review the specific activity of DCs in expanding Natural T-regs and inducing Foxp3(+) T-regs from Foxp3(-) precursors, and further discuss the critical function of DCs in maintaining tolerance at various locations including skin and oral cavity.

Download full-text PDF

Source
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3689032PMC
http://dx.doi.org/10.3389/fimmu.2013.00151DOI Listing

Publication Analysis

Top Keywords

t-regs foxp3-
20
foxp3+ t-regs
20
natural t-regs
16
foxp3- cd4+
12
cd4+ cells
12
t-regs
10
dendritic cells
8
cells
8
regulatory cells
8
dcs
8

Similar Publications

CD4FOXP3Exon2 regulatory T cell frequency predicts breast cancer prognosis and survival.

Sci Adv

January 2025

Istituto per l'Endocrinologia e l'Oncologia Sperimentale "G. Salvatore", IEOS-CNR, Napoli, Italy.

CD4FOXP3 regulatory T cells (T) suppress immune responses to tumors, and their accumulation in the tumor microenvironment (TME) correlates with poor clinical outcome in several cancers, including breast cancer (BC). However, the properties of intratumoral T remain largely unknown. Here, we found that a functionally distinct subpopulation of T, expressing the FOXP3 Exon2 splicing variants, is prominent in patients with hormone receptor-positive BC with poor prognosis.

View Article and Find Full Text PDF

TSLP acts on regulatory T cells to maintain their identity and limit allergic inflammation.

Sci Immunol

January 2025

Laboratory of Molecular Immunology and Immunology Center, National Heart, Lung, and Blood Institute, National Institutes of Health (NIH), Bethesda, MD 20892, USA.

Thymic stromal lymphopoietin (TSLP) is a type I cytokine that promotes allergic responses and mediates type 2 immunity. A balance between effector T cells (T), which drive the immune response, and regulatory T cells (T), which suppress the response, is required for proper immune homeostasis. Here, we report that TSLP differentially acts on T versus T to balance type 2 immunity.

View Article and Find Full Text PDF
Article Synopsis
  • Regulatory T cells (T) help maintain immune balance, but their dysfunction can cause diseases like autoimmunity and rejection of transplanted organs, spurring interest in T cell therapies.
  • The study introduces a new type of CAR-T cell that specifically targets OX40 ligand (OX40L), controlled by a synthetic promoter to enhance effectiveness and stability in treating these conditions.
  • The engineered OX40L-CAR-T cells showed improved activation, suppressing unwanted immune responses more effectively than standard T cells, and demonstrated potential for controlling both graft-versus-host disease and other autoimmune disorders.
View Article and Find Full Text PDF

Cancer-associated SF3B1-K700E mutation controls immune responses by regulating T function via aberrant splicing.

Sci Adv

September 2024

Department of Immunology & Theranostics, Arthur Riggs Diabetes & Metabolism Research Institute, Beckman Research Institute of the City of Hope, Duarte, CA 91010, USA.

Article Synopsis
  • SF3B1-K700E is a common mutation found in hematopoietic cancers that can lead to spontaneous autoimmune issues in mice when expressed in regulatory T cells.
  • This mutation causes T cells to malfunction, evidenced by their inability to prevent colitis, due to an abnormal splicing event that reduces a key cell proliferation regulator.
  • The study also shows that the growth of acute myeloid leukemia is accelerated in older mice, underscoring how cancer mutations can disrupt immune responses and influence cancer progression.
View Article and Find Full Text PDF

Anti-TNFR2 Antibody-Conjugated PLGA Nanoparticles for Targeted Delivery of Adriamycin in Mouse Colon Cancer.

Research (Wash D C)

September 2024

Institute of Chinese Medical Sciences, State Key Laboratory of Quality Research in Chinese Medicine, University of Macau, Macau, China.

High levels of tumor necrosis factor receptor type II (TNFR2) are preferentially expressed by immunosuppressive CD4Foxp3 regulatory T cells (T), especially those present in the tumor microenvironment, as initially reported by us. There is compelling evidence that targeting TNFR2 markedly enhances antitumor immune responses. Furthermore, a broad spectrum of human cancers also expresses TNFR2, while its expression by normal tissue is very limited.

View Article and Find Full Text PDF

Want AI Summaries of new PubMed Abstracts delivered to your In-box?

Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!